US2021177887A1PendingUtilityA1
Compositions and methods for treating elastic fiber breakdown
Est. expiryApr 12, 2038(~11.7 yrs left)· nominal 20-yr term from priority
A61K 31/728A61P 11/00A61K 9/0078A61K 9/0075
57
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present disclosure relates to pharmaceutical compositions capable of regulating elastic fiber. The disclosure further relates to methods of treating elastic fiber-related disorders, such as COPD, by inhalation of low-molecular weight hyaluronic acid.
Claims
exact text as granted — not AI-modifiedWe claim:
1 - 17 . (canceled)
18 . A pharmaceutical composition comprising:
hyaluronic acid, or a pharmaceutically acceptable salt thereof, wherein the hyaluronic acid has a weight average molecular weight (M w ) of about 50 to about 1000 kDa; and a pharmaceutically acceptable excipient, wherein the hyaluronic acid is formulated as a solution of 0.01% to 0.06% w/v.
19 . The pharmaceutical composition of claim 1 , wherein the hyaluronic acid is formulated as a solution of 0.01% to 0.03% w/v.
20 . The pharmaceutical composition of claim 1 , wherein the hyaluronic acid is formulated as a solution of 0.01% w/v.
21 . The pharmaceutical composition of claim 1 , wherein the hyaluronic acid has a weight average molecular weight (M w ) of about 150 kDa.
22 . The pharmaceutical composition of claim 1 , wherein the hyaluronic acid is formulated for inhalation.
23 . The pharmaceutical composition of claim 22 , wherein the hyaluronic acid is formulated for nasal, intrapulmonary, intratracheal, intrabronchial, or intra-alveolar administration.
24 . The pharmaceutical composition of claim 23 , wherein the hyaluronic acid is formulated for intra-alveolar administration.
25 . The pharmaceutical composition of claim 1 , wherein the hyaluronic acid is formulated for administration through a liquid spray device.
26 . The pharmaceutical composition of claim 25 , wherein the liquid spray device is an aerosol device.
27 . The pharmaceutical composition of claim 26 , wherein the aerosol device is a nebulizer or electrohydrodynamic aerosol device.
28 . An inhaler comprising the pharmaceutical composition of claim 1 .
29 . The inhaler of claim 28 , wherein the inhaler is configured to deliver droplets with a size of about 2 μm to about 3 μm.
30 . The inhaler of claim 28 , wherein the inhaler comprises 3 ml of the solution of 0.01% to 0.06% w/v of hyaluronic acid.
31 . The inhaler of claim 28 , wherein the hyaluronic acid is formulated as a solution of 0.01% to 0.03% w/v.
32 . The inhaler of claim 28 , wherein the hyaluronic acid is formulated as a solution of 0.01% w/v.
33 . The inhaler of claim 28 , wherein the inhaler is a liquid spray device.
34 . The inhaler of claim 33 , wherein the liquid spray device is an aerosol device.
35 . The inhaler of claim 34 , wherein the aerosol device is a nebulizer or electrohydrodynamic aerosol device.Join the waitlist — get patent alerts
Track US2021177887A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.